New combo therapy for rare spine tumor shows promise in early trial
NCT ID NCT01407198
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This early-phase study tested the safety of adding nilotinib, a drug that targets a specific growth signal in chordoma cells, to standard radiation therapy for people with high-risk chordoma. The goal was to find the highest safe dose of nilotinib when combined with radiation. Twenty-three participants were enrolled, and researchers monitored side effects to determine the best dose for future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.